Safety Evaluation of SGN-35C in Adult Patients with Advanced Diffuse Large B-Cell Lymphoma, Hodgkin Disease, Peripheral T-Cell Lymphoma, and Anaplastic Large-Cell Lymphoma

The primary objective of this study is to evaluate the **safety** of SGN-35C in adults diagnosed with advanced cancers, specifically focusing on **Diffuse Large B-Cell Lymphoma**, **Hodgkin Disease**, **Peripheral T-Cell Lymphoma**, and **Anaplastic Large-Cell Lymphoma**. Assessing the safety profile of SGN-35C is clinically relevant as it may provide insights into potential adverse effects and inform future therapeutic strategies for these malignancies. No secondary objectives are specified for this study.

The clinical trial involves a total of **122 participants** diagnosed with various types of lymphoma, including **Diffuse Large B-Cell Lymphoma**, Hodgkin Disease, Peripheral T-Cell Lymphoma, and Anaplastic Large-Cell Lymphoma. The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not disclosed further details regarding the general health status of the participants.

The clinical trial is designed to evaluate the safety of **SGN-35C** in adults with advanced cancers, specifically targeting conditions such as **Diffuse Large B-Cell Lymphoma**, **Hodgkin Disease**, **Peripheral T-Cell Lymphoma**, and **Anaplastic Large-Cell Lymphoma**. This study is structured as a Phase 1 trial, which is typically the initial phase in clinical research focused on assessing the safety profile of a new investigational drug. The trial is expected to commence recruitment on August 1, 2024, and is projected to conclude by November 1, 2029. The study employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve comprehensive assessments to confirm the diagnosis and evaluate the participant's overall health status. Following successful screening, participants will be enrolled in the trial and will attend regular follow-up visits. These visits are scheduled to monitor the participant's response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. The frequency and number of follow-up visits will be determined by the specific requirements of the trial phase and the investigational product's safety profile.

The end-of-study visit marks the conclusion of the participant's involvement in the trial. During this visit, final evaluations will be conducted to gather data on the long-term effects of the treatment and to ensure the participant's well-being post-trial. The expected length of participant involvement will vary depending on individual response to the treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously planned to prioritize participant safety while achieving the study's scientific objectives.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be described. The absence of these details limits the ability to provide a comprehensive overview of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on August 1, 2024, with an estimated completion date of November 1, 2029. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a combination of clinical observations and laboratory tests to gather initial efficacy data. The data collection and analysis will adhere to standard clinical trial protocols, ensuring that any efficacy-related findings are systematically recorded and evaluated. The trial will follow a predefined schedule for assessments, which is typical in clinical research to ensure consistency and reliability of the data collected.